Informations of Faculty (English)

Name: Keng-Li Lan, M.D., Ph.D.

Tel: (02)2826-7000 #7121

Fax: (02)2822-5044
Email:
kllan@ym.edu.tw

Current position:

2013 - Present  Associate Professor, The Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

2009 - Present  Attending Physician, The Department of Radiation Oncology, Cancer Treatment Center, Veterans General Hospital, Taipei, Taiwan

Education:

      University of Michigan, Ph.D. in Pharmacology

          National Yang-Ming University, M.D.

Professional Position/Experience:

2008 - 2013    Adjunct assistant Professor, the Institute of Radiological Sciences & Department of Medical Radiation Technology, National Yang-Ming University, Taipei, Taiwan

2004 – 2008    Resident Doctor at the Department of Radiation Oncology, Cancer Treatment Center, Veterans General Hospital, Taipei, Taiwan

2001-2004     Adjunct Instructor, Molecular & Cellular Oncology, MD Anderson Cancer Center, Texas

1999 - 2000    Postdoctoral research fellow, Molecular & Cellular Oncology, MD Anderson Cancer Center, Texas

               (Mentor: Professor Mien-Chie Hung)

1995 - 1999   Graduate Student Research Assistant, Department of Pharmacology, University of Michigan, Ann Arbor, MI

1992 - 1994   Resident doctor, Department of Internal Medicine, Chu-Tong Veterans Hospital, Hsin-Chu, Taiwan

Honor and Awards:

  1. Award of Publication in Radiation Oncology, Cancer Prevention & Treatment Found Frist ation (2010-2011)
  2. Young Investigator Award, Asian Clinical Oncology Society, Gifu Japan (2010)
  3. Innovation in Medical Research Award, Taipei Veterans General Hospital (2014)
  4. We, Innovators Award of Institute for Biotechnology and Medicine Industry (2016)
  5. Innovation in Medical Research Award, Taipei Veterans General Hospital (2017)

Specialty:

         Radiation oncology, Signal Transduction, New drug development, Immunotherapy, Nanotechnology, Target therapy

Research field:

        Radiation oncology, Signal Transduction, New drug development, Immunotherapy, Nanotechnology, Target therapy

Other Information:

Research Projects:

  

Liposomal BikDD mutant gene therapy for murine carcinomatosis models

Taipei Veterans General Hospital (VGH) Research Program (2006)

Investigating the anti-HIF1 activity of Honokiol

Taipei VGH Research Program (2007)

Combination of radiotherapy with BikDD gene therapy

Taipei VGH Research Program (2008)

Development of GM-CSF vaccine targeting VEGFR

Taipei VGH Research Program (2008-2009)

Evaluating the radiosensitizing effect of angiogenesis inhibitors

Taipei VGH Research Program (2009)

Developing GM-CSF-VEGFR fusion vaccine

Taipei VGH Research Program (2010)

Investigating CTLA4-VEGF vaccine

Taipei VGH Research Program (2010)

Optimization of CTLA4 vaccine

Taipei VGH Research Program (2011)

Development of anti-TGF-beta vaccine

Taipei VGH Research Program (2012)

Development of inhibitors against PD-1 and PD-L1

Taipei VGH Research Program (2013)

Preclinical studies of CTLA4-VEGF vaccine

Taipei VGH Research Program (2013)

Mimotopes for Cytotoxic T-Lymphocyte–associated Antigen 4 (CTLA-4)

Taipei VGH Research Program (2014)

Development of anti-CD44 Vaccine

Taipei VGH Research Program (2014)

Identification of potential drug targets related to leukemia inhibitory factor (LIF)

Taipei VGH-University System of Taiwan Research Program (2014)

Development of tumor models for internal radiotherapy

Atomic Energy Council Program (2014)

Mimotopes derived from antibodies against programmed cell death-1 (PD-1)

Taipei VGH Research Program (2015)

Optimization of DNA vaccine

Taipei VGH-Medical Affairs Bureau Ministry of National Defense Program(2015)

Translational Research of CD44 Peptide Vaccines

Taipei VGH Research Program (2015)

Development of anti-EGFRvIII Vaccine 

Taipei VGH Research Program (2016)

Vaccine Targeting VEGF-A and VEGF-C Combined with Radiotherapy 

Taipei VGH Research Program (2016)

Development of vaccines targeting leukemia inhibitory factor 

Taipei VGH-University System of Taiwan Research Program (2017)

Improving the anticancer efficacy of immunocytokine using protein design strategy 

Taipei Veterans General Hospital Research Program (2017-2019)

Identification of Potential Drug Targets Related to Leukemia Inhibitory 

Taipei VGH-University System of Taiwan Research Program (2018)

Preclinical efficacy and toxicity studies of an innovative endostatin-interleukin-2 (endo-IL2) fusion

protein

Ministry of Science and Technology (MOST) Program (2012-2015)

Preclinical Studies of DNA Vaccines Targeting Immune Checkpoint Proteins

MOST program (2014-2016)

Radiolabeled hEGF-ABD Targeting EGFR-expressing Tumors

MOST program (2015-2017)

Development of Radiolabeled Fcy-EGF for Treatment of EGFR expressing Cancers

MOST program (2018)

 

Publications:

1.     Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, Chuang CM. 188Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept. Int J Mol Sci 2017;18.

2.     Kung Y, Lihachev A, Satkauskas S, Lan KL, Chen WS. Electroporation by concentric-type needle electrodes and arrays. Bioelectrochemistry 2017;118:31-37.

3.     Shen YA, Lan KL, Chang CH, Lin LT, He CL, Chen PH, Lee TW, et al. Intraperitoneal (188)Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice. Radiother Oncol 2016;119:282-290.

4.     Li JJ, Lan KL, Chang SF, Chen YF, Tsai WC, Chiang PH, Lin MH, et al. Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System. Bioconjug Chem 2015.

5.     Chang YJ, Hsu WH, Chang CH, Lan KL, Ting G, Lee TW. Combined therapeutic efficacy of Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26- murine colon cancer cells. Mol Clin Oncol 2014;2:380-384.

6.     Liu YM, Liu YK, Lan KL, Lee YW, Tsai TH, Chen YJ. Medicinal Fungus Antrodia cinnamomea Inhibits Growth and Cancer Stem Cell Characteristics of Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2013;2013:569737.

7.     Chang YJ, Hsu CW, Chang CH, Lan KL, Ting G, Lee TW. Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model. Invest New Drugs 2013;31:801-811.

8.     Lan KH, Liu YC, Shih YS, Tsaid CL, Yen SH, Lan KL. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth. Biochem Biophys Res Commun 2013;440:222-228.

9.     Lan KH, Wang YW, Lee WP, Lan KL, Tseng SH, Hung LR, Yen SH, et al. Multiple effects of Honokiol on the life cycle of hepatitis C virus. Liver Int 2012;32:989-997.

10.   Hsu CW, Chang YJ, Chang CH, Chen LC, Lan KL, Ting G, Lee TW. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. Cancer Biother Radiopharm 2012;27:481-489.

11.   Liu CM, Lee WC, Yu CY, Lan KL, Chang CH, Ting G, Lee TW. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model. Oncol Rep 2012;27:678-684.

12.   Chen LC, Wu YH, Liu IH, Ho CL, Lee WC, Chang CH, Lan KL, et al. Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl Med Biol 2012;39:35-43.

13.   Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, et al. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 2012;188:2464-2471.

14.   Lan KH, Shih YS, Chang CA, Yen SH, Lan KL. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells. Biochem Biophys Res Commun 2012;428:292-297.

15.   Lan KL, Lan KH, Sheu ML, Chen MY, Shih YS, Hsu FC, Wang HM, et al. Honokiol inhibits hypoxia-inducible factor-1 pathway. Int J Radiat Biol 2011;87:579-590.

16.   Tsai CC, Chang CH, Chen LC, Chang YJ, Lan KL, Wu YH, Hsu CW, et al. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine 2011;6:2607-2619.

17.   Lan KL, Ou-Yang F, Yen SH, Shih HL, Lan KH. Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer. Clin Exp Metastasis 2010;27:307-318.

18.   Lan KL, Yen SH, Liu RS, Shih HL, Tseng FW, Lan KH. Mutant Bik gene transferred by cationic liposome inhibits peritoneal disseminated murine colon cancer. Clin Exp Metastasis 2007;24:461-470.

19.   Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, Yen SH, et al. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J Hepatol 2007;46:759-767.

20.   Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, Xie X, et al. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006;66:378-384.

21.   Fu Y, Zhong H, Nanamori M, Mortensen RM, Huang X, Lan K, Neubig RR. RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. Methods Enzymol 2004;389:229-243.

22.   Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat 2003;6:129-136.

23.   Wade SM, Lan K, Moore DJ, Neubig RR. Inverse agonist activity at the alpha(2A)-adrenergic receptor. Mol Pharmacol 2001;59:532-542.

24.   Lan KL, Zhong H, Nanamori M, Neubig RR. Rapid kinetics of regulator of G-protein signaling (RGS)-mediated Galphai and Galphao deactivation. Galpha specificity of RGS4 AND RGS7. J Biol Chem 2000;275:33497-33503.

25.   Wade SM, Lim WK, Lan KL, Chung DA, Nanamori M, Neubig RR. G(i) activator region of alpha(2A)-adrenergic receptors: distinct basic residues mediate G(i) versus G(s) activation. Mol Pharmacol 1999;56:1005-1013.

26.   Lan KL, Sarvazyan NA, Taussig R, Mackenzie RG, DiBello PR, Dohlman HG, Neubig RR. A point mutation in Galphao and Galphai1 blocks interaction with regulator of G protein signaling proteins. J Biol Chem 1998;273:12794-12797.

27.   Lan KL, Remmers AE, Neubig RR. Roles of G(o)alpha tryptophans in GTP hydrolysis, GDP release, and fluorescence signals. Biochemistry 1998;37:837-84

 

Patent

  1. 藍耿立,施易昇,張正,顏上惠,藍耿欣(2017) 治療感染性與惡性疾病的標靶化學治療藥物的形成方法, 中華人民共和國發明專利號201210181043.5
  2. 藍耿立,施易昇,張正,顏上惠,藍耿欣(2015) 治療感染性與惡性疾病的標靶化學治療藥物的形成方法, 中華民國(台灣)發明專利核准(發明第 I 486446 )
  3. 藍耿立,施易昇,藍耿欣(2015) 提升感染性與惡性疾病之治療之免疫反應;中華民國(台灣)發明專利核准(發明第 I 496886 )
  4. Lan K-L, Shih Y-S, Lan K-H (2013) Method for Enhancing Immune Response in the Treatment of Infectious and Malignant Diseases US Patent: 8609605
  5. Hung M-C, Lan K-L, Lan K-H, Liu J-C, Ou-Yang F (2011) Targeting proteins to deliver therapeutic or diagnostic reagents. US Patent: 7893033

 

 

HOME